Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and ...

As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...

Two major contributors to reduced health-related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) and lymphoma are muscle weakness and fatigue, according to a study ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Triplet Regimen Yields Promising Response in Advanced-Phase Chronic Myeloid Leukemia ... risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that the first patient has been dosed in ...

Venetoclax, a first-in-class BCL-2 inhibitor, offers a novel treatment approach by targeting cancer cells in the blood ... certain patients with Chronic Lymphocytic Leukemia (CLL), Venetoclax ...

The firms will use nFerence's Agentic AI platform to analyze real-world treatment patterns in 700 patients' charts and inform personalized care.

Thyroid involvement is rare in chronic lymphocytic ... Read more about CLL complications The authors obtained fine-needle aspiration biopsies of the nodules, the results of which showed coarse ...

Biosciences announced the first patient has been dosed in its Phase 2 trial of MB-105, a first-in-class CD5-targeted CAR-T ...